17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis.

      Science (New York, N.Y.)
      Animals, Blood Glucose, metabolism, Diabetes Mellitus, Experimental, Eukaryotic Initiation Factors, Fibroblast Growth Factors, pharmacology, Glucose, Glycogen Synthase, Glycogen Synthase Kinase 3, Hep G2 Cells, Humans, Insulin, Liver, drug effects, Liver Glycogen, biosynthesis, MAP Kinase Signaling System, Male, Mice, Mice, Inbred C57BL, Phosphorylation, Protein Biosynthesis, Proto-Oncogene Proteins c-akt, Ribosomal Protein S6, Signal Transduction

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Fibroblast growth factor (FGF) 19 is an enterokine synthesized and released when bile acids are taken up into the ileum. We show that FGF19 stimulates hepatic protein and glycogen synthesis but does not induce lipogenesis. The effects of FGF19 are independent of the activity of either insulin or the protein kinase Akt and, instead, are mediated through a mitogen-activated protein kinase signaling pathway that activates components of the protein translation machinery and stimulates glycogen synthase activity. Mice lacking FGF15 (the mouse FGF19 ortholog) fail to properly maintain blood concentrations of glucose and normal postprandial amounts of liver glycogen. FGF19 treatment restored the loss of glycogen in diabetic animals lacking insulin. Thus, FGF19 activates a physiologically important, insulin-independent endocrine pathway that regulates hepatic protein and glycogen metabolism.

          Related collections

          Author and article information

          Comments

          Comment on this article